Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

3.31USD
1:30am IST
Change (% chg)

$-0.16 (-4.61%)
Prev Close
$3.47
Open
$3.44
Day's High
$3.45
Day's Low
$3.28
Volume
15,189
Avg. Vol
117,055
52-wk High
$7.44
52-wk Low
$1.90

Latest Key Developments (Source: Significant Developments)

Adamas Pharmaceuticals Appoints Neil Mcfarlane As Chief Executive Officer
Friday, 13 Sep 2019 

Sept 13 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS PHARMACEUTICALS APPOINTS NEIL MCFARLANE AS CHIEF EXECUTIVE OFFICER.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY, LEAD INDEPENDENT DIRECTOR, APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE SUCCEEDS GREGORY WENT.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE NAMED CHIEF EXECUTIVE OFFICER & APPOINTED TO ADAMAS BOARD OF DIRECTORS, EFFECTIVE SEPTEMBER 16.ADAMAS PHARMACEUTICALS INC - GREGORY WENT WILL STEP DOWN FROM BOARD OF DIRECTORS AND TRANSITION TO A STRATEGIC ADVISORY ROLE.ADAMAS PHARMACEUTICALS INC - MCFARLANE MOST RECENTLY SERVED AS CHIEF OPERATING OFFICER OF RETROPHIN INC.  Full Article

Adamas Pharmaceuticals Appoints Neil Mcfarlane As Chief Executive Officer
Friday, 13 Sep 2019 

Sept 13 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS PHARMACEUTICALS APPOINTS NEIL MCFARLANE AS CHIEF EXECUTIVE OFFICER.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY, LEAD INDEPENDENT DIRECTOR, APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE SUCCEEDS GREGORY WENT.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE NAMED CHIEF EXECUTIVE OFFICER & APPOINTED TO ADAMAS BOARD OF DIRECTORS, EFFECTIVE SEPTEMBER 16.ADAMAS PHARMACEUTICALS INC - GREGORY WENT WILL STEP DOWN FROM BOARD OF DIRECTORS AND TRANSITION TO A STRATEGIC ADVISORY ROLE.ADAMAS PHARMACEUTICALS INC - MCFARLANE MOST RECENTLY SERVED AS CHIEF OPERATING OFFICER OF RETROPHIN INC.  Full Article

Adamas Reports Recent Achievements And Financial Results For The Fourth Quarter And Full-Year 2018
Tuesday, 5 Mar 2019 

March 4 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2018.Q4 LOSS PER SHARE $1.06.Q4 EARNINGS PER SHARE ESTIMATE $-1.34 -- REFINITIV IBES DATA.ADAMAS PHARMACEUTICALS - REPORTED GOCOVRI NET PRODUCT SALES OF $13.3 MILLION FOR 3 MONTHS ENDED DEC 31, 2018, VERSUS $0.6 MILLION FOR THREE MONTHS ENDED DEC 31, 2017.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $35 MILLION AND $45 MILLION.  Full Article

BRIEF-Adamas Provides Program Update For ADS-5102 For Multiple Sclerosis Patients With Walking Impairment

* ADAMAS PROVIDES PROGRAM UPDATE FOR ADS-5102 FOR MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT